| |
|
|
|
Akari Therapeutics  
|
|
3.07 0.13 (0.04%) |
01-25 12:16 |
|
Open: |
2.81 |
Pre close: |
2.94 |
Target:
|
4.39
|
|
High: |
3.08 |
Low: |
2.81 |
Resistance:
|
3.76
4.39
|
|
Volume: |
174,490 |
Market Cap: |
118M |
Support:
|
2.53
1.77
|
|
|
|
|
|
Technical Analysis |
|
Moving Averages |
MA(5):
|
3.10
 |
MACD |
MACD(12,26):
|
0.33 |
|
MA(20): |
2.32  |
Signal(12,26,9): |
0.25 |
|
MA(100): |
1.83 |
Stochastic Oscillator |
%K(14,3):
|
58.62 |
|
MA(250): |
1.84 |
%D(3): |
66.46 |
|
Average Volume(K) |
3-Month: |
25938
|
52-Week |
High:
|
3.76 |
|
10-Days: |
60649 |
Low: |
0.87 |
|
RSI |
RSI(14):
|
67.91 |
Change(%): |
60.0 |
|
Financials, Statistics and Valuation |
|
EPS |
-0.636 |
Return on Equity (ttm) |
-447.4 |
Shares Out. (M) |
38.47 |
|
EPS Est. Current Year |
-2.360 |
Return on Assets (ttm) |
-92.4 |
Shares Float (M) |
18.75 |
|
EPS Est. Next Year |
-3.110 |
PEG Ratio |
0.00 |
% Held by Insiders |
26.88 |
|
EPS Est. Next Quarter |
-0.660 |
Qtrly Rev. Growth |
0.0 |
% Held by Institutions |
20.76 |
|
Forward EPS |
-0.100 |
Gross Profit (p.s.) |
0.000 |
Shares Short (K) |
155 |
|
Book Value (p.s.) |
0.140 |
EBITDA (p.s.) |
-0.468 |
P/E |
-4.65 |
|
Sales Per Share |
0.000 |
Qtrly Earnings Growth |
0.00 |
P/BV |
21.14 |
|
Profit Margin |
0.00 |
Operating Cash Flow
(M) |
-16.18 |
P/S |
0.00 |
|
Operating Margin |
0.00 |
Levered Free Cash Flow
(M) |
-6.46 |
P/CF |
-7.04 |
|
|
|
|
|
|
